BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 29073988)

  • 1. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Policy in Poland.
    Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
    Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Policy in Croatia.
    Culig J; Antolic S; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():27-30. PubMed ID: 29073984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Policy in Slovakia.
    Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
    Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greece: Health system review.
    Economou C
    Health Syst Transit; 2010; 12(7):1-177, xv-xvi. PubMed ID: 21330233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulgaria health system review.
    Dimova A; Rohova M; Moutafova E; Atanasova E; Koeva S; Panteli D; van Ginneken E
    Health Syst Transit; 2012; 14(3):1-186. PubMed ID: 22894828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.